ClinicalTrials.gg
TerminatedNCT05968638Updated Oct 9, 2026

Ketogenic Diet in People With Schizophrenia

An interventional study of Regular Diet and Ketogenic Diet in Schizophrenia and Schizo Affective Disorder, sponsored by University of Maryland, Baltimore. Terminated at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Secretary of Health for the State of MD halted all inpatient research that was not federally funded
Updated Oct 9, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Schizophrenia by University of Maryland, Baltimore — 3 open to participants now, 4 under way, none of them phase 3. Schizophrenia · University of Maryland, Baltimore.

Enrollment
50th of 54
4 · median 36
Started
2023
with 2 others
No phase
32 of 63
2 open now
Registered
60th of 63
by date

Among the 63 studies in Schizophrenia by University of Maryland, Baltimore, this one is the 50th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2023, is one of 32 with no phase, and was the 60th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 63 studies in Schizophrenia by University of Maryland, Baltimore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Schizophrenia by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

Schizophrenia is a serious mental disorder with a heterogenous presentation, lack of clear understanding of pathophysiology and only partially effective treatments. First-line antipsychotic drugs block dopamine, but many people continue to suffer from persistent positive or negative symptoms that cannot be fully treated with available medications. Recently, our group has found that dietary modulations have efficacy comparable to antipsychotic medications and that determining which patients could benefit from a personalized treatment framework is critical.

The ketogenic diet consists of low-carbohydrate, moderate protein and high fat intake inducing a state in which ketone bodies in the blood provide energy to the cells. In pharmacologic mouse models a ketogenic diet regimen resulted in complete restoration of normal behaviors, independent of strict caloric restriction and other work has suggested that a ketogenic diet may improve schizophrenia like deficits in rodents. An open label ketogenic diet study in the 1950s reported improvement in schizophrenia symptom. At least 7 additional case reports have found robust improvements or complete resolution of schizophrenia symptoms. Recently a retrospective study found robust and significant improvements in schizophrenia symptoms in 10 schizoaffective disorder patients treated with a ketogenic diet. In addition to psychiatric symptoms, improvements in metabolic outcomes have been demonstrated. However, to date, there have been no published double blind randomized controlled trials evaluating the effects of a ketogenic diet since few sites can conduct inpatient trials and have observation and control for food intake

03

Conditions studied

  • Schizophrenia
  • Schizo Affective Disorder
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18- 64 years
  2. Diagnostic and Statistical Manual (/DSM 5) diagnosis of schizophrenia or schizoaffective disorder
  3. Antipsychotic regimen with no dose change in last 14 days
  4. Minimum score of 45 on BPRS
  5. > 18.5
  6. Ability to consent determined by a score of 10 or greater on the Evaluation to Sign Consent.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females
  2. Type I diabetes or insulin dependent Type II diabetes
  3. Current diagnosis of DSM 5 eating disorder
  4. Heart failure
  5. interval (QTc) prolongation greater than or equal to 500ms
  6. Significant kidney disease

    Indicators for possible acute kidney injury (AKI) or moderate chronic kidney disease (CKD) based on some factors below. Each is not used individually but a clinician will determine based on the following:

    • Creatinine > 1.3mg/dL
    • (GFR) \< 60 mL/min/1.73 m2
    • Renal tubular disorders
    • History of kidney transplantation
  7. Significant liver disease.

    Indicators for possible acute or chronic liver disease. Each is not used individually but a clinician will determine based on the following:

    • Prolonged (INR) greater than or equal to 1.5, elevated and aminotransferases (3x normal upper limit) and/or Complete Blood Count (CBC) abnormalities (thrombocytopenia, anemia)
    • Physical examination abnormalities (jaundice, icteric sclera, asterixis)
    • Alcohol use disorder (AUD) based on DSM 5 criteria for moderate AUD
    • History of liver disease (cirrhosis, Wilson disease, Gilbert disease, chronic hepatitis, hepatitis, primary biliary cirrhosis (PBC), primary Sclerosing Cholangitis (PSC) alpha-1 antitrypsin deficiency, hereditary hemochromatosis, Budd-Chiari syndrome)
    • History of liver transplantation
  8. Porphyria
  9. Genetic disorders that affect fat metabolism (Gaucher disease, Tay-Sachs disease, medium-chain acyl-CoA dehydrogenase deficiency (MCADD)
  10. Carnitine deficiency syndromes (primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency)
  11. Pyruvate kinase deficiency
  12. Gastroparesis
  13. Refusal to eat intervention diet, food allergies or restrictions that the kitchen cannot accommodate, and/or dietary noncompliance with dietary energy needs
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Placebo comparator
    Regular Diet

    Other: Regular Diet

  • Active comparator
    Ketogenic Diet

    Other: Ketogenic Diet

Interventions

  • OtherRegular Diet

    Regular Diet

  • OtherKetogenic Diet

    Ketogenic Diet

06

What researchers measure

Primary outcomes

  1. Assessment of positive and negative symptoms

    Brief Psychiatric Rating Scale (BPRS): The BPRS scale will be the primary outcome measure. It will be administered at baseline and at the end of each week. The BPRS is considered the most widely used symptom rating scale in psychiatric research, is highly sensitive to change, and has excellent interrater reliability with appropriate training of raters. The BPRS assesses the level of 18 symptom constructs such as hostility, suspiciousness, hallucination, and grandiosity. The rater enters a number for each symptom construct that ranges from 1 (not present) to 7 (extremely severe). The score ranges from 18-126, with the higher the number the worse the symptoms.

    Time frame: 3 months

07

Study locations

1 site
  • Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)
    Catonsville, Maryland 21228, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2023 to primary completion in Aug 2025, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Aug 2026 → Aug 2025 and completion Aug 2027 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Aug 1, 2023
StartActual
Sep 1, 2023
Primary completionActual
Aug 1, 2025was Aug 2026
CompletionActual
Aug 1, 2025was Aug 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Secretary of Health for the State of MD halted all inpatient research that was not federally funded
changed Oct 9, 2026
Primary completion
Aug 1, 2026→Aug 1, 2025 (actual)
Oct 9, 2026
Study completion
Aug 1, 2027→Aug 1, 2025 (actual)
Oct 9, 2026
Enrollment
50 (estimated)→4 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Terminated
    Why stopped Secretary of Health for the State of MD halted all inpatient research that was not federally funded
    Primary completion Aug 1, 2026→Aug 1, 2025 (now actual)
    Study completion Aug 1, 2027→Aug 1, 2025 (now actual)
    Enrollment 50 (estimated)→4 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05968638
Responsible party
Deanna Kelly (Chief and Director, Treatment Research Program, University of Maryland, Baltimore) — Principal investigator
First posted
Aug 1, 2023
Start date
Sep 1, 2023
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025
Last update
Oct 9, 2026

Study contacts

Deanna L Kelly, Pharm.D., BCPP
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion